Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Curaleaf Holdings
CURA
Curaleaf Holdings
Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$2.65
36.0% overvalued
intrinsic discount
16 Aug
CA$3.61
Loading
1Y
-17.4%
7D
-14.7%
Author's Valuation
CA$2.7
36.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$2.7
36.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-318m
1b
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$1.5b
Earnings US$22.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.86%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.30%
Calculation
US$22.90m
Earnings '28
x
84.06x
PE Ratio '28
=
US$1.92b
Market Cap '28
US$1.92b
Market Cap '28
/
834.63m
No. shares '28
=
US$2.31
Share Price '28
US$2.31
Share Price '28
Discounted to 2025 @ 6.30% p.a.
=
US$1.92
Fair Value '25
US$1.92
Fair Value '25
Converted to CAD @ 1.3814 USD/CAD Exchange Rate
=
CA$2.65
Fair Value '25
